REMICADE

Dose: 5 mg/kg
Single Dose: 5 (5)
Frequency: 24 hourly
Route: IV Induction
Instructions: at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks (For Crohn's disease). For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue Infliximab in these patients.

Dose: 5 mg/kg
Single Dose: 5 (5)
Frequency: As recommended.
Route: IV infusion
Instructions: Followed by additional 5mg/kg infusion doses at 2 & 6 weeks.

. It is of Synthetic origin. . The Molecular Weight of Infliximab is 144190.30. It is weakly alkaline drug and Its pKa is 8.25.

Infliximab

The severe or irreversible adverse effects of Infliximab, which give rise to further complications include Hepatitis, Jaundice, Jaundice, Blood dyscrasias, Cholestasis, Deaths, blood dyscrasias.Infliximab produces potentially life-threatening effects which include Active tuberculosis, Invasive fungal infections. which are responsible for the discontinuation of Infliximab therapy.The symptomatic adverse reactions produced by Infliximab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Diarrhea, Abdominal pain, Nausea and vomiting, Back pain, dizziness.

'Infliximab is primarily indicated in conditions like Ankylosing spondylitis, Crohn''s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis.'

No data regarding the interactions of Infliximab was found.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Patients treated with Infliximab are at increased risk for developing serious infections that may lead to hospitalization or death. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Infliximab use and during therapy.1, 2 Treatment for latent infection should be initiated prior to Infliximab use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens. The risks and benefits of treatment with Infliximab should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Infliximab, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.